# US 2020/0390901 A1 · Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and - phosphonates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390901 A1
- Document ID: US20200390901A1
- Status: Published application
- Kind: A1
- Application number: 16/977,680
- Filed: 2019-03-06
- Published: 2020-12-17
- Earliest claimed: 2018-03-07
- Assignees: Forschungsverbund Berlin E.V.; Ludwig-Maximilians-Universitat Munchen
- Applicants: Forschungsverbund Berlin E.V.; Ludwig-Maximilians-UniversitäT MüNchen
- Inventors: Christian HACKENBERGER; Alice Leonie BAUMANN; Marc-André KASPER; Stephen BYRNE; Jonas HELMA-SMETS; Heinrich LEONHARDT; Tina STOSCHECK; Marcus GERLACH; Dominik SCHUMACHER
- Web page: https://patentgrep.com/patent/US20200390901A1

## CPC

- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- C07F 9/4015: {Esters of acyclic unsaturated acids}
- C07F 9/4071: {the ester moiety containing a substituent or a structure which is considered as characteristic}
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are novel conjugates and processes for the preparation thereof. A process for the preparation of alkene- or alkyne-phosohonothiolates and -phosphonates comprises the step of: reacting a compound of formula (I) with a thiol-containing molecule of formula (II) wherein represents an amino acid, a peptide, a protein, an antibody, a nucleotide, an oligonucleotide, a saccharide, a polysaccharide, a polymer, an optionally substituted C1-C8-alkyl, an optionally substituted phenyl, or an optionally substituted aromatic 5- or 6-membered heterocyclic system; resulting in a compound of formula (III).

## Claims

### Claim 1

Process for the preparation of a phosphonothiolate or phosphonate comprising the step of:
reacting a compound of formula (I)
wherein
represents a double bond or triple bond;
X represents R3—C when is a triple bond;
X represents (R3 R4)C when is a double bond;
Y represents S or O;
R1 represents an optionally substituted aliphatic or aromatic residue;
R3 represents H or C1-C8-alkyl;
R4 represents H or C1-C8-alkyl; and
represents an aliphatic or aromatic residue;
with a thiol-containing molecule of formula (II)
wherein represents an amino acid, a peptide, a protein, an antibody, a nucleotide, an oligonucleotide, a saccharide, a polysaccharide, a polymer, an optionally substituted C1-C8-alkyl, an optionally substituted phenyl, or an optionally substituted aromatic 5- or 6-membered heterocyclic system;
resulting in a compound of formula (III)
wherein
represents a bond if in a compound of formula (I) represents a double bond; or
represents a double bond if in a compound of formula (I) represents a triple bond; and
, , R1, X and Y are as defined above.

### Claim 2 (depends on 1)

The process according to claim 1, wherein represents a double bond, X represents (R3 R4)C, R3 and R4 independently represent H or C1-C5-alkyl and represents a bond.

### Claim 3 (depends on 1)

The process according to claim 1, wherein represents a triple bond, X represents R3—C, R3 represents H or C1-C8-alkyl and represents a double bond.

### Claim 4

The process according to any one of the preceding claims, wherein Y is S.

### Claim 5

The process according to any one of the preceding claims, further comprising a preparation of a compound of formula (I), said preparation comprising:
reacting a compound of formula (IV)
wherein R1, X, Y, and are as defined in any one of the preceding claims;
with an oxidant, such as e.g. tert-butyl hydroperoxide (tBu-OOH), meta-chloroperoxybenzoic acid (mCPBA), hydrogen peroxide (H2O2), iodine (I2), potassium peroxymonosulphate, or oxygen (O2), to form the compound of formula (I).

### Claim 6 (depends on 5)

The process according to claim 5, further comprising a preparation of the compound of formula (IV), said preparation comprising:
reacting, in sequential order, a phosphorus trihalide (X), preferably PCl3, with (i) R1—OH (XI), (ii)
wherein R2 independently represents C1-C8-alkyl, (iii)
wherein Hal represents a halogen selected from the group consisting of Cl, Br and I, preferably Br, and (iv)
to form the compound of formula (IV);
wherein R1, X, Y, and are as defined in any one of the preceding claims.

### Claim 7 (depends on 4)

The process according to claim 4, further comprising a preparation of a compound of formula (I), said preparation comprising:
reacting a compound of formula (V)
with a compound of formula (VIa) or (VIb):
to form a compound of formula (I);
wherein EWG represents an electron withdrawing group, said electron withdrawing group preferably being selected from the group consisting of
wherein # indicates the position of S; Hal represents a halogen selected from the group consisting of Cl, Br and I, preferably Cl, and
wherein R1, X, and are as defined in any one of the preceding claims.

### Claim 8 (depends on 7)

The process according to claim 7, wherein is a double bond and X represents (R3 R4)C, wherein R3 and R4 are as defined in any one of the preceding claims.

### Claim 9

Process for the preparation of a phosphonothiolate or phosphonate comprising the step of:
Reacting a compound of formula (I*)
wherein
V represents C1-C8-alkyl, preferably methyl, ethyl or propyl, more preferably methyl;
X represents (R3 R4)C;
wherein , Y, R1, R3 and R4 are as defined in any one of the preceding claims,
with a thiol-containing molecule of formula (II)
wherein is as defined in any one of the preceding claims;
resulting in a compound of formula (III*)
wherein , , V, R1, X and Y are as defined in any one of the preceding claims.

### Claim 10 (depends on 9)

The process according to claim 9, wherein Y is S.

### Claim 11 (depends on 9, 10)

The process according to claim 9 or 10, further comprising a preparation of a compound of formula (I*), said preparation comprising:
reacting a compound of formula (IV*)
wherein X represents (R3 R4)C, and Y, R1, R3, R4, V and are as defined in any one of the preceding claims;
with an oxidant, such as e.g. tert-butyl hydroperoxide (tBu-OOH), meta-chloroperoxybenzoic acid (mCPBA), hydrogen peroxide (H2O2), iodine (I2), potassium peroxymonosulphate, or oxygen (O2), to form the compound of formula (I*).

### Claim 12 (depends on 11)

The process according to claim 11, further comprising a preparation of the compound of formula (IV*), said preparation comprising:
reacting, in sequential order, a phosphorus trihalide (X), preferably PCl3, with (i) R1—OH (XI), (ii)
wherein R2 independently represents C1-C8-alkyl, (iii)
wherein Hal represents a halogen selected from the group consisting of Cl, Br and I, preferably Br, and X represents (R3 R4)C, and (iv)
to form the compound of formula (IV*);
wherein R1, R3, R4, V, Y and are as defined in any one of the preceding claims.

### Claim 13 (depends on 10)

The process according to claim 10, further comprising a preparation of a compound of formula (I*), said preparation comprising:
reacting a compound of formula (V*)
with a compound of formula (VIa) or (VIb)
to form a compound of formula (I*);
wherein EWG represents an electron withdrawing group, said electron withdrawing group preferably being selected from the group consisting of
wherein # indicates the position of S; Hal represents a halogen selected from the group consisting of Cl, Br and I, preferably Cl; and
wherein X represents (R3 R4)C; and R1, R3, R4, V and are as defined in any one of the preceding claims.

### Claim 14

The process according to any one of the preceding claims, wherein R1 represents C1-C8-alkyl optionally substituted with at least one of (C1-C8-alkoxy)n wherein n is 1, 2, 3, 4, 5 or 6, F, Cl, Br, I, —N2, —N(C1-C8-alkyl)H, —NH2, —N3, —N(C1-C8-alkyl)2, ═O, C3-C8-cycloalkyl, —S—S—(C1-C8-alkyl), hydroxy-(C1-C8-alkoxy)n wherein n is 1, 2, 3, 4, 5 or 6, C2-C8-alkenyl, C2-C8-alkynyl; or
R1 represents phenyl optionally independently substituted with at least one of C1-C8-alkyl, (C1-C8-alkoxy)n wherein n is 1, 2, 3, 4, 5 or 6, F, Cl, I, Br, —NO2, —N(C1-C8-alkyl)H, —NH2 or —N(C1-C8-alkyl)2; or
R1 represents a 5- or 6-membered heteroaromatic system such as pyridyl;
preferably, R1 represents C1-C8-alkyl, C1-C8-alkyl substituted with —S—S—(C1-C8-alkyl), C1-C8-alkyl substituted with (C1-C8-alkoxy)n wherein n is 1, 2, 3, 4, 5 or 6, C1-C8-alkyl substituted with optionally substituted phenyl; or phenyl; or phenyl substituted with —NO2.

### Claim 15

The process according to any one of the preceding claims, wherein R1 represents methyl, ethyl, propyl or butyl, more preferably methyl or ethyl.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The process according to any one of claims 1 to 13, wherein R1 represents
wherein R10, R11, R12 and R13 each independently represent hydrogen or C1-C8-alkyl;
and # represents the position of O.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The process according to any one of claims 1 to 13, wherein R1 represents C1-C8-alkyl substituted with phenyl, said phenyl being further substituted with
wherein Z is O or NH, preferably O, and wherein # represents the position of said phenyl.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The process according to any one of claims 1 to 13, wherein R1 represents C1-C8-alkyl substituted with phenyl, said phenyl being further substituted with
and wherein # represents the position of said phenyl.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The process according to any one of claims 1 to 13, wherein R1 represents
with n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
with n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, wherein # represents the position of O.

### Claim 20

The process according to any one of the preceding claims, wherein represents a small molecule such as, for example, an optionally substituted C1-C8-alkyl, preferably ethyl, —CH2-phenyl,
wherein # indicates the position of the Y; or
represents an optionally substituted phenyl; or
represents a radioactive or non-radioactive nuclide, biotin, a reporter enzyme, a nucleotide, an oligonucleotide, a fluorophore such as CY5 or EDANS, an amino acid, a peptide, or an optionally substituted 5- or 6-membered heteroaromatic system; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein represents:
biotin; or
represents CY5 or EDANS; or
represents phenyl, optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of C1-C8-alkyl, C1-C8-alkoxy, halogen, —CN, —NO2, —NH2, —N(C1-C8-alkyl), —N(C1-C8-alkyl)2-COOH, —COO(C1-C8-alkyl), —O—C(O)—(C1-C8-alkyl), —C(O)N—(C1-C8-alkyl), —N(H)—C(O)—(C1-C8-alkyl) preferably optionally substituted with one substituent selected from the group consisting of C1-C8-alkoxy, —COOH, —COO(C1-C8-alkyl and NO2; or
represents C1-C8-alkyl, optionally substituted with at least one substituent selected from the group consisting of C3-C8-cycloalkyl; heterocyclyl with 3 to 8 ring members wherein the heteroatom(s) are selected from N, O, S; C1-C8-alkoxy; halogen; —CN; —NO2; —NH2; —N(C1-C8-alkyl); —N(C1-C8-alkyl)2; —COOH; —COO(C1-C8-alkyl); —O—C(O)—(C1-C8-alkyl); —CONH2; —C(O)N(C1-C8-alkyl)2; —C(O)NH—(C1-C8-alkyl); —N(H)—C(O)—(C1-C8-alkyl), preferably C1-C8-alkoxy, —COOH, —COO(C1-C8-alkyl and NO2, phenyl or a heteroaromatic system, a monosaccharide, a polysaccharide, a peptide, a protein, an antibody, a nucleotide, an oligonucleotide, a polymer, an amino acid, a fluorophor, a protein tag (substituent 1st generation), wherein a substituent 1st generation may again optionally be substituted with C3-C8-cycloalkyl; heterocyclyl with 3 to 8 ring members wherein the heteroatom(s) are selected from N, O, S; C1-C8-alkoxy; halogen; —CN; —NO2; —NH2; —N(C1-C8-alkyl); —N(C1-C8-alkyl)2; —COOH; —COO(C1-C8-alkyl); —O—C(O)—(C1-C8-alkyl); —CONH2; —C(O)N(C1-C8-alkyl)2; —C(O)NH—(C1-C8-alkyl); —N(H)—C(O)—(C1-C8-alkyl), preferably C1-C8-alkoxy, —COOH, —COO(C1-C8-alkyl and NO2, phenyl or a heteroaromatic system (substituents 2nd generation) and wherein a substituent 2nd generation may be substituted again by at least one substituent selected from the same group and wherein such substitution may go until generation 3, 4, 5, 6, 7, 8, 9 or 10; or
represents an amino acid, a peptide, a protein, an antibody, a nucleotide, an oligonucleotide, a saccharide, a polysaccharide, a polymer, an optionally substituted C1-C8-alkyl, an optionally substituted phenyl, or an optionally substituted aromatic 5- or 6-membered heterocyclic system; wherein optionally the further comprises a linker that is bound to the Y; or
represents an amino acid, a peptide, a protein, an antibody, a nucleotide or an oligonucleotide; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein represents a drug, a protein tag, or a fluorophore such as CY5 or EDANS, biotin, a protein, a peptide, an antibody or an oligonucleotide; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein represents a linker or a linker-drug conjugate.

### Claim 24

The process according to any one of the preceding claims, wherein represents an amino acid, a peptide, a protein, an antibody, a nucleotide or an oligonucleotide.

### Claim 25

The process according to any one of the preceding claims, wherein represents an antibody, preferably an IgG antibody, more preferably a Cetuximab or a Trastuzumab or a Brentuximab; a protein, preferably a GFP protein or eGFP-protein, an albumin, a tripeptide, preferably a peptide of formula (VIII)
or of formula (IX)
wherein # represents the position of S.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein
represents an antibody and
represents a protein tag, or a fluorophore such as CY5 or EDANS, biotin, a peptide, a protein, an oligonucleotide, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein
represents a protein and
represents a protein tag, or a fluorophore such as CY5 or EDANS, biotin, a peptide, an antibody, a protein, an oligonucleotide, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein
represents a peptide and
represents a protein tag, or a fluorophore such as CY5 or EDANS, biotin, a peptide, a protein, an oligonucleotide, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein
represents an amino acid and
represents a protein tag, or a fluorophore such as CY5 or EDANS, biotin, a peptide, a protein, an oligonucleotide, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein
represents an antibody and
represents a linker, a drug, or a linker-drug conjugate.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein
represents a nucleotide and
represents a peptide, a protein, a protein tag, an antibody, an oligonucleotide, a fluorophore such as CY5 or EDANS, biotin, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein
represents a nucleotide and
represents a linker.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein
represents an oligonucleotide and
represents a peptide, a protein, a protein tag, an antibody, an oligonucleotide, a fluorophore such as CY5 or EDANS, biotin, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The process according to any one of claims 1 to 19, wherein
represents an oligonucleotide and
represents a linker.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 26, 27, 28, 29, 31, 33)

The process according to any one of claims 1 to 22, 26 to 29, 31 and 33, wherein represents an amino acid, a peptide, a nucleotide or an oligonucleotide, wherein the amino acid, peptide, nucleotide or oligonucleotide is bound to a solid support, wherein optionally the further comprises a linker that is bound to the Y.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 28, 29, 31, 32, 33, 34, 35)

The process according to any one of claims 1 to 25, 28 to 29, 31 to 34 and 35, wherein represents an amino acid, a peptide, a nucleotide or an oligonucleotide, wherein the amino acid, peptide, nucleotide or oligonucleotide is bound to a solid support.

### Claim 37

Process for the preparation of a compound of formula (I) or formula (I*), said method comprising:
(I) reacting a compound of formula (Ia)
of formula (I*a)
wherein
L represents a linker suitable for binding to an amino acid, a peptide, a nucleotide or an oligonucleotide; and
, X, Y, V and R1 are as defined in any one of the preceding claims,
with an amino acid, a peptide, a nucleotide or an oligonucleotide, wherein the amino acid, the peptide, the nucleotide or the oligonucleotide is bound to a solid support,
resulting in a compound of formula (Ib) or (I*b),
wherein Z represents the amino acid, the peptide, the nucleotide or the oligonucleotide, wherein the amino acid, the peptide, the nucleotide or the oligonucleotide is bound to the solid support; and
(II) cleaving the compound of formula (Ib) or formula (I*b) from the solid support to give the compound of formula (I) or formula (I*):
wherein represents the amino acid, the peptide, the nucleotide or the oligonucleotide bound to the Y through the linker L, and
, X, Y, V and R1 are as defined above.

### Claim 38 (depends on 37)

The process according to claim 37, wherein the linker L is
wherein # indicates the position of the Y, and m and n are each, independently, an integer of from 0 to 20, 0 to 15, 1 to 10, 1 to 8, 1 to 6, 1 to 4, 1 to 3, 1 to 2, or 1, preferably m is 1 and n is 1.

### Claim 39 (depends on 37, 38)

The process according to claim 37 or 38, wherein the compound of formula (Ia) or (I*a) is reacted with a peptide bound to a solid support or an oligonucleotide bound to a solid support, preferably with a peptide bound to a solid support.

### Claim 40 (depends on 37, 38, 39)

The process according to any one of claims 37 to 39, wherein the cleaving is carried out under acidic conditions.

### Claim 41 (depends on 37, 38, 39, 40)

The process according to any one of claims 37 to 40, further comprising reacting the compound of formula (I) or formula (I*) with a compound of formula (II) as defined in any one of the preceding claims.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The process according to any one claims 1 to 36, wherein the
and the
are in the same molecule.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The process according to any one of claims 1 to 36, wherein the
and the
are in the same molecule.

### Claim 44

A compound of formula (I)
wherein , , R1, X and Y are as defined in any one of the preceding claims.

### Claim 45 (depends on 44)

The compound according to claim 44, wherein, represents a double bond, X represents (R3 R4)C, and R3 and R4 independently represent H or C1-C8-alkyl.

### Claim 46 (depends on 44)

The compound according to claim 44, wherein represents a triple bond, X represents R3—C, and R3 represents H or C1-C8-alkyl.

### Claim 47

A compound of formula (I*)
wherein X represents (R3 R4)C, and R1, R3, R4, V, Y and are as defined in any one of the preceding claims.

### Claim 48

A compound of formula (III)
wherein
represents a bond and X represents (R3 R4)C, wherein R3 and R4 independently represent H or C1-C8-alkyl; or
represents a double bond and X represents R3C, wherein R3 represents H or C1-C8-alkyl; and
, , R1, and Y are as defined in any one of the preceding claims.

### Claim 49

A compound of formula (III*)
wherein X represents (R3 R4)C, and , , V, Y, R1, R3 and R4 are as defined in any one of the preceding claims.

### Claim 50 (depends on 44, 45, 46, 47, 48, 49)

The compound according to any one of claims 44 to 49, wherein Y is S.

### Claim 51 (depends on 44, 45, 46, 47, 48, 49, 50)

The compound according to any one of claims 44 to 50, wherein R1 represents C1-C8-alkyl optionally substituted with at least one of (C1-C8-alkoxy)n wherein n is 1, 2, 3, 4, 5 or 6, F, Cl, Br, I, —NO2, —N(C1-C8-alkyl)H, —NH2, —N3, —N(C1-C8-alkyl)2, ═O, C3-C8-cycloalkyl, —S—S—(C1-C8-alkyl), hydroxy-(C1-C8-alkoxy)n wherein n is 1, 2, 3, 4, 5 or 6, C2-C8-alkenyl, C2-C8-alkynyl; or
R1 represents phenyl optionally independently substituted with at least one of C1-C8-alkyl, (C1-C8-alkoxy)n wherein n is 1, 2, 3, 4, 5 or 6, F, Cl, I, Br, —NO2, —N(C1-C8-alkyl)H, —NH2 or —N(C1-C8-alkyl)2; or
R1 represents a 5- or 6-membered heteroaromatic system such as pyridyl;
preferably, R1 represents C1-C8-alkyl, C1-C8-alkyl substituted with —S—S—(C1-C8-alkyl), C1-C8-alkyl substituted with (C1-C8-alkoxy)n wherein n is 1, 2, 3, 4, 5 or 6, C1-C8-alkyl substituted with optionally substituted phenyl; or phenyl; or phenyl substituted with —NO2.

### Claim 52 (depends on 44, 45, 46, 47, 48, 49, 50, 51)

The compound according to any one of claims 44 to 51, wherein R1 represents methyl, ethyl, propyl or butyl, more preferably methyl or ethyl.

### Claim 53 (depends on 44, 45, 46, 47, 48, 49, 50)

The compound according to any one of claims 44 to 50, wherein R1 represents
wherein R10, R11, R12 and R13 each independently represent hydrogen or C1-C8-alkyl;
and # represents the position of 0.

### Claim 54 (depends on 44, 45, 46, 47, 48, 49, 50)

The compound according to any one of claims 44 to 50, wherein R1 represents C1-C8-alkyl substituted with phenyl, said phenyl being further substituted with
wherein Z is O or NH, preferably O, and wherein # represents the position of said phenyl.

### Claim 55 (depends on 44, 45, 46, 47, 48, 49, 50)

The compound according to any one of claims 44 to 50, wherein R1 represents C1-C8-alkyl substituted with phenyl, said phenyl being further substituted with
and wherein # represents the position of said phenyl.

### Claim 56 (depends on 44, 45, 46, 47, 48, 49, 50)

The compound according to any one of claims 44 to 50, wherein R1 represents
with n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
with n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, wherein # represents the position of O.

### Claim 57 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 44 to 56, wherein represents a small molecule such as, for example, an optionally substituted C1-C8-alkyl, preferably ethyl, —CH2-phenyl,
wherein # indicates the position of the Y; or
represents an optionally substituted phenyl; or
represents a radioactive or non-radioactive nuclide, biotin, a reporter enzyme, a nucleotide, an oligonucleotide, a fluorophore such as CY5 or EDANS, an amino acid, a peptide, or an optionally substituted 5- or 6-membered heteroaromatic system; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 58 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 44 to 56, wherein represents:
biotin; or
represents CY5 or EDANS; or
represents phenyl, optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of C1-C8-alkyl, C1-C8-alkoxy, halogen, —CN, —NO2, —NH2, —N(C1-C8-alkyl), —N(C1-C8-alkyl)2-COOH, —COO(C1-C8-alkyl), —O—C(O)—(C1-C8-alkyl), —C(O)N—(C1-C8-alkyl), —N(H)—C(O)—(C1-C8-alkyl) preferably optionally substituted with one substituent selected from the group consisting of C1-C8-alkoxy, —COOH, —COO(C1-C8-alkyl and NO2; or
represents C1-C8-alkyl, optionally substituted with at least one substituent selected from the group consisting of C3-C8-cycloalkyl; heterocyclyl with 3 to 8 ring members wherein the heteroatom(s) are selected from N, O, S; C1-C8-alkoxy; halogen; —CN; —NO2; —NH2; —N(C1-C8-alkyl); —N(C1-C8-alkyl)2; —COOH; —COO(C1-C8-alkyl); —O—C(O)—(C1-C8-alkyl); —CONH2; —C(O)N(C1-C8-alkyl)2; —C(O)NH—(C1-C8-alkyl); —N(H)—C(O)—(C1-C8-alkyl), preferably C1-C8-alkoxy, —COOH, —COO(C1-C8-alkyl and NO2, phenyl or a heteroaromatic system, a monosaccharide, a polysaccharide, a peptide, a protein, an antibody, a nucleotide, an oligonucleotide, a polymer, an amino acid, a fluorophor, a protein tag (substituent 1st generation), wherein a substituent 1st generation may again optionally be substituted with C3-C8-cycloalkyl; heterocyclyl with 3 to 8 ring members wherein the heteroatom(s) are selected from N, O, S; C1-C8-alkoxy; halogen; —CN; —NO2; —NH2; —N(C1-C8-alkyl); —N(C1-C8-alkyl)2; —COOH; —COO(C1-C8-alkyl); —O—C(O)—(C1-C8-alkyl); —CONH2; —C(O)N(C1-C8-alkyl)2; —C(O)NH—(C1-C8-alkyl); —N(H)—C(O)—(C1-C8-alkyl), preferably C1-C8-alkoxy, —COOH, —COO(C1-C8-alkyl and NO2, phenyl or a heteroaromatic system (substituents 2nd generation) and wherein a substituent 2nd generation may be substituted again by at least one substituent selected from the same group and wherein such substitution may go until generation 3, 4, 5, 6, 7, 8, 9 or 10; or
represents an amino acid, a peptide, a protein, an antibody, a nucleotide, an oligonucleotide, a saccharide, a polysaccharide, a polymer, an optionally substituted C1-C8-alkyl, an optionally substituted phenyl, or an optionally substituted aromatic 5- or 6-membered heterocyclic system; wherein optionally the further comprises a linker that is bound to the Y; or
represents an amino acid, a peptide, a protein, an antibody, a nucleotide or an oligonucleotide; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 59 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 44 to 56, wherein represents a drug, a protein tag, or a fluorophore such as CY5 or EDANS, biotin, a protein, a peptide, an antibody or an oligonucleotide; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 60 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 44 to 56, wherein represents a linker or a linker-drug conjugate.

### Claim 61 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The compound according to any one of claims 48 to 60, wherein represents an amino acid, a peptide, a protein, an antibody, a nucleotide or an oligonucleotide.

### Claim 62 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The compound according to any one of claims 48 to 61, wherein represents an antibody, preferably an IgG-antibody, more preferably a Cetuximab or a Trastuzumab or a Brentuximab; a protein, preferably a GFP protein or eGFP-protein, an albumin, a tripeptide, preferably a peptide of formula (VIII)
or of formula (IX)
wherein # represents the position of S.

### Claim 63 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 48 to 56, wherein
represents an antibody and
represents a protein tag, or a fluorophore such as CY5 or EDANS, biotin, a peptide, a protein, an oligonucleotide, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 64 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 48 to 56, wherein
represents a protein and
represents a protein tag, or a fluorophore such as CY5 or EDANS, biotin, a peptide, an antibody, a protein, an oligonucleotide, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 65 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 48 to 56, wherein
represents a peptide and
represents a protein tag, or a fluorophore such as CY5 or EDANS, biotin, a peptide, an antibody, a protein, an oligonucleotide, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 66 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 48 to 56, wherein
represents an amino acid and
represents a protein tag, or a fluorophore such as CY5 or EDANS, biotin, a peptide, a protein, an oligonucleotide, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 67 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 48 to 56, wherein
represents an antibody and
represents a linker, a drug, or a linker-drug conjugate.

### Claim 68 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 48 to 56, wherein
represents a nucleotide and
represents a peptide, a protein, a protein tag, an antibody, an oligonucleotide, a fluorophore such as CY5 or EDANS, biotin, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 69 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 48 to 56, wherein
represents a nucleotide and
represents a linker.

### Claim 70 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 48 to 56, wherein
represents an oligonucleotide and
represents a peptide, a protein, a protein tag, an antibody, an oligonucleotide, a fluorophore such as CY5 or EDANS, biotin, or a small molecule; wherein optionally the further comprises a linker that is bound to the Y.

### Claim 71 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound according to any one of claims 48 to 56, wherein
represents an oligonucleotide and
represents a linker.

### Claim 72 (depends on 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, 65, 66, 68, 70)

The compound according to any one of claims 44 to 59, 61 to 66, 68 and 70, wherein
represents an amino acid, a peptide, a nucleotide or an oligonucleotide, wherein the amino acid, peptide, nucleotide or oligonucleotide is bound to a solid support,
wherein optionally the further comprises a linker that is bound to the Y, preferably wherein the compound is a compound of formula.

### Claim 73 (depends on 72)

The compound according to claim 72, wherein the compound is a compound of formula (I) or formula (I*).

### Claim 74 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 65, 66, 68, 69, 70, 71, 72)

The compound according to any one of claims 48 to 62, 65 to 66, 68 to 71 and 72 wherein represents an amino acid, a peptide, a nucleotide or an oligonucleotide, wherein the amino acid, peptide, nucleotide or oligonucleotide is bound to a solid support.

### Claim 75

A kit comprising a solid support, and
a compound of formula (Ia)
and/or a compound of formula (I*a)
wherein L is a linker suitable for binding to an amino acid, a peptide, a nucleotide or an oligonucleotide; and
wherein , R1, X, Y, and V are as defined in any one of the preceding claims.

### Claim 76 (depends on 75)

The kit of claim 75, wherein the linker L is
wherein # indicates the position of the Y, and m and n are each, independently, an integer of from 0 to 20, 0 to 15, 1 to 10, 1 to 8, 1 to 6, 1 to 4, 1 to 3, 1 to 2, or 1, preferably m is 1 and n is 1.

### Claim 77 (depends on 75, 76)

The kit of claim 75 or 76, further comprising one or more of an amino acid, one or more of a peptide, one or more of a nucleotide, and/or one or more of an oligonucleotide.

### Claim 78

A compound of formula (IIIa)
wherein
represents a bond and X represents (R3 R4)C; or
represents a double bond and X represents R3—C; and
, , R1, X and Y are as defined in any one of the preceding claims.

### Claim 79

A compound of formula (III*a)
wherein X represents (R3 R4)C, and , , V, Y, R1, R3, and R4 are as defined in any one of the preceding claims.
